The report provides a detailed understanding and analysis of how and why companies enter animal health partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of 269 animal health agreements announced in the life sciences since 2017.
The report takes the reader through a comprehensive review animal health deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering animal health partnering deals.
The report presents financial deal term values for animal health deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the animal health partnering field; both the leading deal values and most active animal health dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
Online deal records of actual animal health deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of animal health dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in animal health dealmaking since 2017, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading animal health deals since 2017. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in animal health dealmaking with a brief summary followed by a comprehensive listing of animal health deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of animal health partnering deals signed and announced since Jan 2017, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of animal health partnering deals signed and announced since Jan 2017. The chapter is organized by specific animal health technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by animal health partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in animal health partnering and dealmaking since 2017.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of animal health technologies and products.
This report provides details of 269 animal health agreements announced in the life sciences since 2017.
The report takes the reader through a comprehensive review animal health deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering animal health partnering deals.
The report presents financial deal term values for animal health deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the animal health partnering field; both the leading deal values and most active animal health dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
Online deal records of actual animal health deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of animal health dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in animal health dealmaking since 2017, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading animal health deals since 2017. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in animal health dealmaking with a brief summary followed by a comprehensive listing of animal health deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of animal health partnering deals signed and announced since Jan 2017, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of animal health partnering deals signed and announced since Jan 2017. The chapter is organized by specific animal health technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by animal health partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in animal health partnering and dealmaking since 2017.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of animal health technologies and products.
Global Animal Health Partnering Terms and Agreements 2017-2024 provides the reader with the following key benefits:
- In-depth understanding of animal health deal trends since 2017
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual animal health contracts entered into by leading biopharma companies
- Identify most active animal health dealmakers since 2017
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report Scope
Global Animal Health Partnering Terms and Agreements 2017 to 2024 is intended to provide the reader with an in-depth understanding and access to animal health trends and structure of deals entered into by leading companies worldwide.Animal Health Partnering Terms and Agreements includes:
- Trends in animal health dealmaking in the biopharma industry since 2017
- Access to headline, upfront, milestone and royalty data
- Access to animal health contract documents
- Leading animal health deals by value since 2017
- Most active animal health dealmakers since 2017
In Global Animal Health Partnering Terms and Agreements 2017 to 2024, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in animal health dealmaking
Chapter 3 - Leading animal health deals
Chapter 4 - Most active animal health dealmakers
Chapter 5 - Animal health contracts dealmaking directory
Appendices
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbCellera Biologics
- Ab E Discovery
- Absorption Systems
- AcuraBio
- AdaptVac
- Adisseo
- ADM
- Advanced Animal Diagnostics
- Aeronics
- AgBiome
- AGC Biologics
- Agricultural Research Organization
- Aimia Pet Health
- AKL Research and Development
- Akston Biosciences
- Algenex
- ALK-Abello
- ALR Technologies
- Altro Pharmaceuticals
- Alveolus
- Alveo Technologies
- American Regent
- American Veterinary Medical Foundation
- Anatara Lifesciences
- Angany
- Animal Allergy Clinical Laboratories
- AnimalBiome
- Animalcare
- Animal Clinical Investigation
- Animal Life Sciences
- Anivive Lifesciences
- Ankyra Therapeutics
- Apacor
- Applied BioSciences
- Applied DNA Sciences
- Aptimmune Biologics
- Aratana Therapeutics
- Arcturus Therapeutics
- Argenta
- Aridis Pharmaceuticals
- Arysta LifeScience
- AskAt
- Assisi Animal Health
- Atomwise
- Aurelius Biotherapeutics
- Aurinia Pharmaceuticals
- Australian Research Council
- Avacta
- Avivagen
- Basepaws
- BASF
- Bayer
- Bayer Animal Health
- Belharra Therapeutics
- Better Choice Company
- Better Choice Products
- Big Barker
- BioChek
- BioCopy
- BioInvent
- BioIVT
- BiomEdit
- BioTecon Diagnostics
- Blacksmith Medicines
- Blue Buffalo Company
- BodeVet
- Boehringer Ingelheim
- Boehringer Ingelheim Vetmedica
- Bond Pet Foods
- Boragen
- Brainomix
- Broad Institute
- Buhler
- Calysta Energy
- CannaSoul Analytics
- CannPal Animal Therapeutics
- CAPInnoVet
- Cardiff University
- cbdMD
- Celsee
- Central Institute for Experimental Animals
- Centrovet
- Ceva Sante Animale
- Charles River Laboratories
- Choom
- Colorado State University
- Cornell University
- Cornerstone Animal Health
- COTA
- Covenant Animal Health Partners
- Covetrus
- Cresilon
- CSA Medical
- CSIRO
- CURE Pharmaceutical
- Curon Biopharmaceutical
- CVM Ecografía
- Daiichi Sankyo
- Danish Innovation Fund
- Dawn Health
- Dechra Pharmaceuticals
- Deinove
- Delf
- Department of Defense
- Destination Pet
- Diversigen
- Domes Pharma
- Dovetail Genomics
- Dragonfly Therapeutics
- DSM
- DW Healthcare
- Dyadic International
- Elanco
- ELIAS Animal Health
- Emollivet
- Energesis Pharmaceuticals
- Envigo
- EPiQ Animal Health
- epitoMAP
- Epivax
- eQcell
- EQT
- Esteve
- Ethos Discovery
- Ethos Veterinary Health
- Eurocine Vaccines
- Evah
- Evax
- Evonik Industries
- Evotec
- Evvivax
- Express Scripts
- Eyebiotech
- Eyegate Pharmaceuticals
- ezyVet
- Fatro
- FDA Center for Veterinary Medicine
- Felix Biotechnology
- Flagship Pioneering
- Food and Drug Administration (FDA)
- Formation Bio
- Forte Biotechnology
- Fraunhofer Institute for Cell Therapy and Immunology
- Front Range Laboratories
- FSD Pharma
- Gallant Therapeutics
- GE Healthcare
- Gencove
- Genelux
- Genetic Veterinary Sciences
- Ginkgo BioWorks
- Global Access Diagnostics
- Global Dx
- Global Stem Cell Technology
- Globion
- GNA Biosolutions
- Gnubiotics Sciences
- Government of Australia
- Greenlight Biosciences
- Grovet
- GrowSafe Systems
- Gryphon Investors
- HappyBond
- Heiland
- HemPup
- Hendrix Genetics
- Henry Schein
- Heska
- Hill's Pet Nutrition
- Horizon Discovery
- Huvepharma
- IdentiGEN
- IDEXX Laboratories
- Ilender
- Illumina
- Immune Therapeutics
- Immunomic Therapeutics
- Impact NRS
- Imugene
- IncellDx
- India Globalization Capital
- Infinovo Medical
- Innovate UK
- Innovet
- Inovalon
- Inovet
- Inphilco
- Insilico Medicine
- Institute of Virology and Immunology
- IntelGenx
- Intrexon
- Invetx
- Jaguar Health
- Jenga Biosciences
- JP Equine Services
- Jurox
- Kahu Vet Group
- Kane Biotech
- Kansas State University
- Karyopharm Therapeutics
- Kemin Industries
- KeraVet Bio
- Kermode Biotechnologies
- Kincell Bio
- Kindred Bio
- Kiora Pharmaceuticals
- Konica Minolta
- KulKote
- KVP International
- Laboratorios Adler
- Lacuna Diagnostics
- Leiber
- LexaGene
- LIC Automation
- LightDeck Therapeutics
- Liiv Organics
- Likarda
- LineaRx
- Lipidor
- LiteCure Medical
- Livestock Improvement
- Loop Genomics
- LSPediA
- Lumosa Therapeutics
- Lygos
- Lytix Biopharma
- Magdalena Biosciences
- Magiar Chilena
- Marrone Bio Innovations
- Mars Petcare
- MBF Therapeutics
- MBP Solutions
- Med-Pharmex
- MedGene Bioscience
- MediCann Handels
- MedinCell
- MediSapiens
- Merck and Co
- Merck Animal Health
- Midori USA
- Miller Veterinary Supply East
- Mimi’s Rock
- Mitsubishi Tanabe Pharma
- Moderna
- Moleculin Biotech
- Mologic
- Morris Animal Foundation
- Mountain Valley MD
- MSD Animal Health
- MWI Animal Health
- MyoKardia
- MYOS
- Nanomix
- NanoSmart Pharmaceuticals
- National Institute for Biotechnology in the Negev
- National Veterinary Associates
- Nature-Cide
- Neogen
- Neptune Technologies & Bioressources
- Nerio Therapeutics
- NeuroCycle Therapeutics
- NewLeaf Brands
- New Ruipeng Group
- Nextmune
- Nexvet
- Nirvana Group
- Nong San Viet
- Nortev
- Novovet
- Novozymes
- Nrgene
- Nufarm
- Nuritas
- NutraMax
- NutriQuest
- NWO.ai
- NXTGEN
- NYtor
- Ochre Bio
- Ocular Therapeutix
- Ology Bioservices
- Oncology Pharma
- Ontera
- OpenAI
- Orion
- Pacific Biosciences
- Pacific GeneTech
- PARI
- Pathogens and Environmental Solutions
- Pearl Bio
- Pebble Labs
- Penn Veterinary Supply
- Performance Livestock Analytics
- Perrigo
- Pestmaster Services
- PetCareRx
- Petco
- PetDx
- PetIQ
- PetLife Pharmaceuticals
- PetMed Express
- Petriage
- Pfizer
- PharmaCielo
- PHAXIAM Therapeutics
- Phibro Animal Health
- Phyto Animal Health
- Plandai Biotechnology
- PlantForm
- Pond Technologies
- POSCO International
- Poultry Sense
- Precigen
- Prelude Therapeutics
- Primordial Genetics
- ProBioGen
- ProFound Therapeutics
- ProtonDx
- Provet
- PulseVet
- Purdue Research Foundation
- Purdue University
- PureKana
- Purina
- Qorvo Biotechnologies
- Quantified Ag
- Queensland University of Technology
- Redbarn Pet Products
- Regen BioPharma
- Regeneron Pharmaceuticals
- RegenLab
- Rejuvenate Bio
- Reliance Animal Health Partners
- Revive & Restore
- Revo Squared
- Riemser
- Ripe Technology
- Saiba Animal Health
- Sanofi
- Sasaeah Pharmaceutical
- Science Biotech
- Scil Animal Care
- Seed Mena
- Senestech
- Sentrx Animal Care
- Sharp Edge Labs
- Simulations Plus
- SIRE Veterinario
- Skout’s Honor Pet Supply Company
- Skyline Vet Pharma
- Sleip
- Sonoma Pharmaceuticals
- Sound Technologies
- Southwest Research Institute
- SRx Health
- STEM Animal Health
- Stonehaven Incubate
- Structured Monitoring Products
- Sumitomo Dainippon Pharma
- Syngenta
- Synthetic Genomics
- Syntr Health Technologies
- SynWorld Technologies
- Takis Biotech
- Target Specialty Products
- Techcyte
- Technology Acceleration Partners
- TeleVet
- Telomir Pharmaceuticals
- Tetra Bio-Pharma
- Tetracore
- Tiba Biotech
- Titan Pharmaceuticals
- Torigen Pharmaceuticals
- Toronto Innovation Acceleration Partners
- Trans Ova Genetics
- Trianni
- TriRx Pharmaceutical Services
- Tufts University
- Twist Bioscience
- UNION Therapeutics
- University of California
- Davis
- University of Connecticut
- University of Glasgow
- University of Illinois Urbana-Champaign
- University of Liverpool
- University of Prince Edward Island
- University of Queensland
- University of Surrey
- University of Vermont
- University of Zurich
- US Department of Agriculture
- Valent Biosciences
- VCA Antech
- VCP
- Vence
- Verios Agro
- VERT
- Vet-Allergy
- Vetcor
- Veterinary Pharmacology Research Foundation
- Vetigenics
- Vetnique Labs
- VetNOW
- Vetophage
- Vetoquinol
- Vets First Choice
- Victor Medical
- Victor Medical Company
- Vida Concepts
- Vigil Neuroscience
- Vimian Group
- Virbac
- Vita Bee Health
- VitalPet
- Vitanova Biomedical
- Vium
- Vivaldis
- VolitionRX
- Vuja De Sciences
- Vytelle
- Wanda Fish Technologies
- Wedgewood Pharmacy
- Wildlife Pharmaceuticals
- Woodley Equipment Company
- World Pet Care Products Company
- Zander Therapeutics
- Zenfold Sustainable Technologies
- Zenoaq
- Zenyaku Kogyo
- Zivo Bioscience
- Zoetis
- Zomedica
- Zydus Cadila
- Zymeworks
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
